Wang F, Liu Y, Zhang T, Hou X, Xin Y, Xie G
iScience. 2025; 28(3):111952.
PMID: 40060904
PMC: 11889568.
DOI: 10.1016/j.isci.2025.111952.
Miller W, Mishra A, Sheedy C, Bond A, Gardner B, Montell D
bioRxiv. 2025; .
PMID: 39990418
PMC: 11844498.
DOI: 10.1101/2025.02.11.637707.
Chen J, Fang M, Li Y, Ding H, Zhang X, Jiang X
Life Med. 2025; 3(4):lnae031.
PMID: 39872863
PMC: 11749001.
DOI: 10.1093/lifemedi/lnae031.
Gou Q, Yan B, Duan Y, Guo Y, Qian J, Shi J
Adv Sci (Weinh). 2024; 12(5):e2412205.
PMID: 39665172
PMC: 11792004.
DOI: 10.1002/advs.202412205.
Mosenlechner M, Schlosser D, Braumuller S, Dorfer L, Mannes M, Kawach R
Shock. 2024; 63(3):448-455.
PMID: 39637172
PMC: 11882169.
DOI: 10.1097/SHK.0000000000002512.
A pan-allelic human SIRPα-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response.
Niu X, Wang C, Jiang H, Gao R, Lu Y, Guo X
Antib Ther. 2024; 7(3):266-280.
PMID: 39257438
PMC: 11384143.
DOI: 10.1093/abt/tbae022.
Deciphering the role of CD47 in cancer immunotherapy.
Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P
J Adv Res. 2024; 63:129-158.
PMID: 39167629
PMC: 11380025.
DOI: 10.1016/j.jare.2023.10.009.
Promising immunotherapeutic approaches for primary effusion lymphoma.
Panaampon J, Okada S
Explor Target Antitumor Ther. 2024; 5(3):699-713.
PMID: 38966176
PMC: 11220309.
DOI: 10.37349/etat.2024.00242.
The Immune Response of Cancer Cells in Breast and Gynecologic Neoplasms.
Rakoczy K, Kaczor J, Soltyk A, Szymanska N, Stecko J, Drag-Zalesinska M
Int J Mol Sci. 2024; 25(11).
PMID: 38892394
PMC: 11172873.
DOI: 10.3390/ijms25116206.
From mechanism to therapy: the journey of CD24 in cancer.
Zhao K, Wu C, Li X, Niu M, Wu D, Cui X
Front Immunol. 2024; 15:1401528.
PMID: 38881902
PMC: 11176514.
DOI: 10.3389/fimmu.2024.1401528.
Harnessing the innate immune system by revolutionizing macrophage-mediated cancer immunotherapy.
Reghu G, Vemula P, Bhat S, Narayanan S
J Biosci. 2024; 49.
PMID: 38864238
PMC: 11286319.
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
Vaccaro K, Allen J, Whitfield T, Maoz A, Reeves S, Velarde J
J Clin Invest. 2024; 134(9).
PMID: 38483480
PMC: 11060739.
DOI: 10.1172/JCI169315.
Tolerating CD47.
Isenberg J, Montero E
Clin Transl Med. 2024; 14(2):e1584.
PMID: 38362603
PMC: 10870051.
DOI: 10.1002/ctm2.1584.
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.
Osorio J, Smith P, Knorr D, Ravetch J
Cancer Cell. 2023; 41(12):2051-2065.e6.
PMID: 37977147
PMC: 10842210.
DOI: 10.1016/j.ccell.2023.10.007.
From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B, Jenkins M, Best S, Freytag S, Prasad K, Holst J
Signal Transduct Target Ther. 2023; 8(1):400.
PMID: 37857607
PMC: 10587102.
DOI: 10.1038/s41392-023-01637-8.
Ferritin-based nanomedicine for disease treatment.
Zhu Y, Zhu Y, Cao T, Liu X, Liu X, Yan Y
Med Rev (2021). 2023; 3(1):49-74.
PMID: 37724111
PMC: 10471093.
DOI: 10.1515/mr-2023-0001.
Structure, Function, and Molecular Landscapes of the Aging Retina.
Zhu J, Tarachand S, Abdulwahab Q, Samuel M
Annu Rev Vis Sci. 2023; 9:177-199.
PMID: 37196423
PMC: 10524587.
DOI: 10.1146/annurev-vision-112122-020950.
Cellular Membrane Localization of Innate Immune Checkpoint Molecule CD47 Is Regulated by Radixin in Human Pancreatic Ductal Adenocarcinoma Cells.
Kobori T, Ito Y, Sawada Y, Urashima Y, Ito T, Obata T
Biomedicines. 2023; 11(4).
PMID: 37189735
PMC: 10136002.
DOI: 10.3390/biomedicines11041117.
Synergistic effect of CD47 blockade in combination with cordycepin treatment against cancer.
Feng C, Chen R, Fang W, Gao X, Ying H, Zheng X
Front Pharmacol. 2023; 14:1144330.
PMID: 37138855
PMC: 10149837.
DOI: 10.3389/fphar.2023.1144330.
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden M, Zwarthoff S, Arends R, Reinieren-Beeren I, Parade M, Driessen-Engels L
J Immunother Cancer. 2023; 11(4).
PMID: 37068796
PMC: 10186489.
DOI: 10.1136/jitc-2022-006567.